Oncology
With a 100% response rate (small sample size) in AR-mutant patients, MRT-2359 validates the GSPT1 degradation thesis, signaling a major disruption for the post-taxane mCRPC landscape. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional
Oncology
Immunome’s Phase 3 RINGSIDE trial delivers a potential best-in-class profile, combining profound tumor shrinkage with a convenient once-daily regimen. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * A New High-Water Mark in
Oncology
In a crowded HR+/HER2- landscape, Relay Therapeutics has potentially delivered the 'Holy Grail' of PI3K inhibition—demonstrating robust PFS benefits without the metabolic penalties that have plagued the asset class for a decade. * These analyses reflect my personal opinions and may include input from multiple sources. They
Oncology
In a decisive move to disrupt the stagnation of salvage therapy, MAIA Biotechnology initiates a pivotal Phase 3 trial. With a mechanism that turns 'cold' tumors 'hot' and survival data tripling the standard of care, Ateganosine is poised to be a major target for Big Pharma—
Oncology
The Phase III lidERA study marks the first significant advancement in adjuvant endocrine therapy in nearly 25 years, offering a superior oral SERD alternative to standard-of-care. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional
paltusotine
Paltusotine aims to replace depot octreotide and lanreotide injections with oral daily dosing for carcinoid syndrome. The SST2 agonist targets the same pathway while eliminating the burden of clinic-administered shots.
Oncology
Phase 1 data confirms extracellular FLT3 binding efficacy regardless of mutational status, offering a potential breakthrough for refractory subsets. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Perspective Data presented today at